“…An important limitation of this strategy is that it assumes that the date of delivery can be pinpointed. If delivery is unexpectedly early, as may occur in antidepressant-treated women, 26,27 this strategy may not be implementable, and if delivery is delayed for any reason, prolongation of a low-dose or a drugfree period may risk relapse of depressive illness, which defeats the purpose of having exposed the offspring to the drug during pregnancy. The taperand-transiently-discontinue strategy is intuitively appealing, and a register-based study by Warburton et al 28 indeed found that respiratory distress and convulsions were each less likely to occur in neonates who had not been exposed to selective serotonin reuptake inhibitors in the 2 weeks before delivery (n = 2,122) relative to those who were exposed (n = 1,605); however, this finding disappeared in a propensity-matched analysis (n = 239 per group), implying that maternal illness characteristics may also drive the clinical features of PNAS.…”